Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Merck
Mallinckrodt
McKinsey
McKesson

Last Updated: January 27, 2023

Piflufolastat f-18 - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for piflufolastat f-18 and what is the scope of freedom to operate?

Piflufolastat f-18 is the generic ingredient in one branded drug marketed by Progenics Pharms Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Piflufolastat f-18 has eighty-three patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for piflufolastat f-18
International Patents:83
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 1
Patent Applications: 80
What excipients (inactive ingredients) are in piflufolastat f-18?piflufolastat f-18 excipients list
DailyMed Link:piflufolastat f-18 at DailyMed
Recent Clinical Trials for piflufolastat f-18

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lantheus Medical ImagingEarly Phase 1
M.D. Anderson Cancer CenterEarly Phase 1

See all piflufolastat f-18 clinical trials

Pharmacology for piflufolastat f-18

US Patents and Regulatory Information for piflufolastat f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for piflufolastat f-18

Country Patent Number Title Estimated Expiration
European Patent Office 3699162 HÉTÉRODIMÈRES D'ACIDE GLUTAMIQUE (HETERODIMERS OF GLUTAMIC ACID) See Plans and Pricing
China 102171187 PSMA-binding agents and uses thereof See Plans and Pricing
World Intellectual Property Organization (WIPO) 2010014933 See Plans and Pricing
Taiwan I492761 See Plans and Pricing
Spain 2926912 See Plans and Pricing
Canada 2987744 AGENTS DE LIAISON AU PSMA ET SES UTILISATIONS (PSMA-BINDING AGENTS AND USES THEREOF) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
McKinsey
Mallinckrodt
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.